Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis 1Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Novartis 1Q Results

Key growth drivers include Entresto with $1.9 billion in sales, up 34%, and Cosentyx with sales of $1.3 billion, up 23%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
1Q Revenues: $11.8 billion (+10%)
1Q Earnings: $2.7 billion (+25%)
Comments: Key growth drivers include Entresto with $1.9 billion in sales, up 34%, Cosentyx sales of $1.3 billion, up 23%, Kesimpta sales of $637 million, up 66%, Kisqali sales of $627 million, up 51%, Pluvicto sales of $310 million, up 47% and Leqvio sales of $151 million, up 136%. Promacta sales were down 5% to $520 million. Jakavi sales were up 15% to $478 million. Tafinlar+Mekinist sales were up 3% to $474 million. Xolair sales were $399 million, up 13%. Tasigna sales were down 15% to $395 million. Ilaris sales were $356 million, up 9%. Lucentis sales were down 25% to $314 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters